Novel Study from Yale University Utilizes Daxor’s Blood Volume Analyzer (BVA-100®) to Uncover Important Mechanism for Drug Empagliflozin
Daxor Corporation - Closed End Fund (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: GlobeNewswire
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from The Yale University School of Medicine that was presented on November 16th at the American Heart Association Scientific Sessions in Philadelphia, PA. “Empaglilozin (sold as “Jardiance”) has shown unexpected benefits in reducing heart failure (HF) mortality for diabetic patients, making it one of the most talked-about discoveries in recent years. Researchers at Yale utilized Daxor’s unique technology to analyze the volume shifts associated with the drug and were able to determine that there is a significant and sustained blood volume shift that is unique to this diuretic that may explain why diabetic HF patients have been shown in recent trials to benefit from its use. This data is concordant with other recently published studies showing that controlli
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation - Closed End Fund news events
Weekly update
A roundup of the hottest topics
DXR
News
- DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24GlobeNewswire
- Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitGlobeNewswire
- Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device [Yahoo! Finance]Yahoo! Finance
- Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic DeviceGlobeNewswire
- Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024GlobeNewswire
DXR
Analyst Actions
- 9/9/24 - Ascendiant Capital
DXR
Sec Filings
- 11/21/24 - Form NPORT-P
- 9/10/24 - Form N-PX
- 8/29/24 - Form NPORT-P
- DXR's page on the SEC website